We are monitoring the impact of COVID-19 & Recession alarm on Europe Alzheimer’s Disease Therapeutics And Diagnostics Market Get in touch with us for detailed analysis Know More
Share on

Europe Alzheimer’s Disease Therapeutics and Diagnostics Market Research Report – Segmented By Therapeutics, Diagnostics & Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) – Industry Size, Share, Trends & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 2155
Pages: 133

The size of the Europe Alzheimer’s Disease Therapeutics and Diagnostics Market was worth USD 2956.33 Million in 2022 and estimated to be growing at a CAGR of 4.76%, to reach USD 3730.18 Million by 2027.

The market for treatments and diagnostics for Alzheimer's disease in Europe is primarily driven by an aging population, increased R&D expenditure, a high prevalence of Alzheimer's and neurodegenerative disorders, and increased life expectancy in the general population.

The growth rate of the Alzheimer's disease therapeutics and diagnostics market in Europe is also fuelled by expanding the number of drug development channels and investing in biomarkers for drug development. The market for Alzheimer's disease therapies and diagnostics in Europe is driven by a rise in new diagnostics for early diagnosis and more specialized medication development, and an increase in life expectancy in the general population. According to the United Nations' Global Population Prospects 2019, one out of every six people on the planet will be over 65 by 2050, up from one out of every eleven in 2019. In addition, the market is expected to benefit from an increase in clinical trials related to diagnosing and treating Alzheimer's disease.

Other key drivers expected to drive the market expansion include the rising prevalence of chronic diseases like dementia, increased channel drug development, venture into biomarkers for drug development, and increased advanced diagnostics for early diagnosis and more targeted medication development.

However, a lack of surrogate indicators for drug research and development, insufficient testing resources, and lengthy, unpredictable procedures are forecasted to limit the market's growth. Alzheimer's disease is soon becoming a severe public health concern as the number of persons affected grows. Alzheimer's disease affects around 5.3 million people in the United States and 35 million people worldwide. As Alzheimer's disease spreads worldwide, new techniques for diagnosing and treating the condition are urgently needed. Early detection of Alzheimer's disease (AD) is complex. Early symptoms of Alzheimer's disease (AD) are typically neglected because the indicators are moderate. The physical changes in the brain and central nervous system symptoms are not generally visible on medical scans. This limitation is critical because late-stage diagnosis provides patients with symptomatic relief through drugs, negating any potential benefit from early therapy and diagnosis.

This research report on the European Alzheimer's disease therapeutics and diagnostics market has been segmented and sub-segmented into the following categories.

By Therapeutics: 

  • Marketed Drugs
    • NMDA Receptor Antagonists
    • Cholinesterase Inhibitors
  • Pipeline Drugs

By Diagnostics: 

  • Computed tomography scan
  • Electroencephalography
  • Lumbar puncture test
  • Magnetic resonance imaging
  • Positron emission tomography
  • Others

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Geographically, the European region is one of the prominent regions for AD therapeutics and diagnostics. Populations in Europe are aging, and this grows the frequency of Alzheimer’s disease, and roughly around 9 million people in the EU are projected to have dementia by 2030 – approaching twice the population of Denmark. Therefore, increasing R&D activity and a strong pipeline of disease-modifying drugs are the crucial factors driving the market's growth in this region.

In the following years, dementia cases in the United Kingdom are predicted to increase, propelling the industry under investigation even higher. The Dementia Discovery Fund (DDF) has invested GBP 250 million in developing new dementia medications. Furthermore, by 2030, the aging population (those over 65) is expected to increase significantly. According to the National Clinical Trials Registry, approximately 25 active clinical trials for Alzheimer's disease in the United Kingdom (NCT). Market growth in the United Kingdom is expected to be aided by such factors.

By 2030, Italy's 13.93 million aging population will have grown to 16.46 million. This is expected to push the government to take the lead in developing viable medications. According to the National Centre for Trials and Evaluation, there are currently 16 active Alzheimer's disease trials. According to Alzheimer Europe, Italy initiated the 'Interceptor Project' in December 2017 to detect persons at risk of Alzheimer's disease. The market in Italy is expected to increase in the following years due to current research-friendly public policy frameworks.

KEY MARKET PLAYERS:

Leading companies have applied tactics such as mergers & acquisitions, collaborations, and joint ventures to gain a strong foothold in the market. As a result, the major companies dominating the Alzheimer’s Disease Therapeutics and Diagnostics market in this region are Abbvie Inc., Pfizer Inc., AC Immune SA, Eisai Co Ltd., Allergan PLC, Novartis AG, Amarantus Bioscience Holdings, H. Lundbeck A/S, Anavex LifeSciences, Avid Radiopharmaceuticals, Forest Laboratories Inc., Axon Neuroscience, Daiichi Sankyo Co, TauRx Therapeutics Ltd, Eli Lilly, F. Hoffmann La Roche AG, Johnson & Johnson, GE Healthcare, Janssen Pharmaceuticals, etc.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Therapeutics                              

                                5.1.1 Introduction           

                                5.1.2 Marketed Drugs   

                                                5.1.2.1 NMDA Receptor Antagonists

                                                5.1.2.2 Cholinesterase Inhibitors

                                5.1.3 Pipeline Drugs       

                                5.1.4  Y-o-Y Growth Analysis, By Therapeutics    

                                5.1.5  Market Attractiveness Analysis, By Therapeutics  

                                5.1.6  Market Share Analysis, By Therapeutics    

                5.2 Diagnostics                 

                                5.2.1 Introduction           

                                5.2.2 Computed tomography scan           

                                5.2.3 Electroencephalography   

                                5.2.4 Lumbar puncture test        

                                5.2.5 Magnetic resonance imaging          

                                5.2.6 Positron emission tomography      

                                5.2.7 Others      

                                5.2.8  Y-o-Y Growth Analysis, By Diagnostics        

                                5.2.9  Market Attractiveness Analysis, By Diagnostics      

                                5.2.10  Market Share Analysis, By Diagnostics     

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Therapeutics

                                                6.1.3.3 By Diagnostics

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Therapeutics

                                                6.1.4.3 By Diagnostics

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Therapeutics

                                                6.1.5.3 By Diagnostics

                6.2 U.K                 

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Abbvie Inc.                 

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Pfizer Inc.                    

                8.3 AC Immune SA                          

                8.4 Eisai Co Ltd.                

                8.5 Allergan PLC                               

                8.6 Novartis AG                

                8.7 Amarantus Bioscience Holdings                         

                8.8 H. Lundbeck A/S                       

                8.9 Anavex LifeSciencescs                           

                8.10 Avid Radiopharmaceuticals                               

                8.11 Forest Laboratories Inc.                      

                8.12 Axon Neuroscience                              

                8.13 Daiichi Sankyo Co                   

                8.14 TauRx Therapeutics Ltd                       

                8.15 Eli Lilly                         

                8.16 F. Hoffmann La Roche AG                  

                8.17 Johnson & Johnson                              

                8.18 GE Healthcare                         

                8.19 Janssen Pharmaceuticals                    

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  1. Europe Alzheimer’s Disease Therapeutics and Diagnostics Market, By Therapeutics, From 2022 - 2027 (USD Billion)
  2. Europe Marketed Drugs Market, By Region, From 2022 - 2027 (USD Billion)
  3. Europe Pipeline Drugs Market, By Region, From 2022 - 2027 (USD Billion)
  4. Europe Alzheimer’s Disease Therapeutics and Diagnostics Market, By Diagnostics, From 2022 - 2027 (USD Billion)
  5. Europe Computed tomography scan Market, By Region, From 2022 - 2027 (USD Billion)
  6. Europe Electroencephalography Market, By Region, From 2022 - 2027 (USD Billion)
  7. Europe Lumbar puncture test Market, By Region, From 2022 - 2027 (USD Billion)
  8. Europe Magnetic resonance imaging Market, By Region, From 2022 - 2027 (USD Billion)
  9. Europe Positron emission tomography Market, By Region, From 2022 - 2027 (USD Billion)
  10. Europe Other diagnostics Market, By Region, From 2022 - 2027 (USD Billion)
  11. U.K. Alzheimer’s Disease Therapeutics and Diagnostics Market, By Therapeutics, From 2022 - 2027 (USD Billion)
  12. U.K. Alzheimer’s Disease Therapeutics and Diagnostics Market, By Diagnostics, From 2022 - 2027 (USD Billion)
  13. Germany Alzheimer’s Disease Therapeutics and Diagnostics Market, By Therapeutics, From 2022 - 2027 (USD Billion)
  14. Germany Alzheimer’s Disease Therapeutics and Diagnostics Market, By Diagnostics, From 2022 - 2027 (USD Billion)
  15. France Alzheimer’s Disease Therapeutics and Diagnostics Market, By Therapeutics, From 2022 - 2027 (USD Billion)
  16. France Alzheimer’s Disease Therapeutics and Diagnostics Market, By Diagnostics, From 2022 - 2027 (USD Billion)
  17. Italy Alzheimer’s Disease Therapeutics and Diagnostics Market, By Therapeutics, From 2022 - 2027 (USD Billion)
  18. Italy Alzheimer’s Disease Therapeutics and Diagnostics Market, By Diagnostics, From 2022 - 2027 (USD Billion)
  19. Spain Alzheimer’s Disease Therapeutics and Diagnostics Market, By Therapeutics, From 2022 - 2027 (USD Billion)
  20. Spain Alzheimer’s Disease Therapeutics and Diagnostics Market, By Diagnostics, From 2022 - 2027 (USD Billion)
  21. Europe Alzheimer’s Disease Therapeutics and Diagnostics Market, By Marketed Drugs, From 2022 - 2027 (USD Billion)
  22. Europe NMDA Receptor Antagonists Market, By Region, From 2022 - 2027 (USD Billion)
  23. Europe Cholinesterase Inhibitors Market, By Region, From 2022 - 2027 (USD Billion)
  24. U.K. Alzheimer’s Disease Therapeutics and Diagnostics Market, By Marketed Drugs, From 2022 - 2027 (USD Billion)
  25. Germany Alzheimer’s Disease Therapeutics and Diagnostics Market, By Marketed Drugs, From 2022 - 2027 (USD Billion)
  26. France Alzheimer’s Disease Therapeutics and Diagnostics Market, By Marketed Drugs, From 2022 - 2027 (USD Billion)
  27. Italy Alzheimer’s Disease Therapeutics and Diagnostics Market, By Marketed Drugs, From 2022 - 2027 (USD Billion)
  28. Spain Alzheimer’s Disease Therapeutics and Diagnostics Market, By Marketed Drugs, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample